-
Healthcare Brands International - UK
-
At Healthcare Brands International (HBI), we are committed to acquiring, developing and investing in differentiated healthcare products. In short we will translate innovative science into meaningful consumer brands.
The first incarnation of HBI was funded with over �85 million of venture capital from leading international venture capital investors. We are a team of experienced OTC blue chip business professionals with an unrivalled network of partners and contacts around the world (with particular strength in Europe). We bring core skills in consumer marketing and brand development and combine with partners providing in-market operational and regulatory expertise.
HBI brought Sambucol, a black elderberry based , powerful anti-oxidant ,immune system enhancing flu remedy, to market in Europe, Asia and North America, before an exit to Pharmacare.
HBI achieved a direct OTC MRP licence approval throughout Europe for Erazaban, a docosanol based alternative treatment for cold sores, and launched through a network of marketing partners.
HBI acquired Antula Healthcare in Sweden and turned it into the major Nordic OTC company before selling to Meda AB.
Having sold the existing assets HBI is now able to focus on acquisition of OTC products and speciality pharma assets in Europe. We will also focus on commercialising innovative products with meaningful and substantiated differentiation that meet a relevant and yet unmet or only partially met consumer need and thereby help grow the overall self-medication market.
Click here to read an interview with Barry Clare in OTC Bulletin by Deborah Wilkes
